Bizarre Patents
A self defense weapon formed as a memo pad and which is easily held by a person's fingers, therefore making it possible to provide protection from a mugger and also to quickly and easily write a record or a message without failure of missing or forgetting significant information under a stressful situation.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8182816 | Methods of treating cancer Disclosed are methods of treating subjects having cancers including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods... | 05/22/2012 |
| 8178098 | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflam... | 05/15/2012 |
| 8142783 | Methods of treating an inflammatory condition involving VAP-1-mediated adhesion with VAP-1-specific antibodies Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-... | 03/27/2012 |
| 8084031 | Method for the treatment of inflammatory disorders A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1. ... | 12/27/2011 |
| 8071097 | Apoptotic anti-IgE antibodies The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. ... | 12/06/2011 |
| 8071096 | Anti-C5aR antibodies and uses thereof The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are ... | 12/06/2011 |
| 8057795 | Method of reducing the activation of Th2 lymphocytes We previously reported that NKG2A, a key inhibitory ligand for HLA-E, is expressed on activated TH2, but not TH1, cells. Here we measured cytokine expression in ex vivo TH2 cells and in a mouse model of asthma upon activation with antiCD3/28 and challenge with an NK... | 11/15/2011 |
| 8048421 | Agonist antibody to human thrombopoietin receptor This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl). More particularly, this invention provides an agonist antibody to a human thrombopoietin receptor, wherein the agonist antibody comprises: antibody constant regions ... | 11/01/2011 |
| 7959918 | Methods for treating vascular disease Compositions and methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic ... | 06/14/2011 |
| 7955598 | Therapeutic agent for chronic arthritides diseases of childhood-related diseases A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient. ... | 06/07/2011 |
| 7947272 | Compositions and methods of tolerizing a primate to an antigen Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably ... | 05/24/2011 |
| 7939076 | Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 int... | 05/10/2011 |
| 7931901 | T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as... | 04/26/2011 |
| 7927592 | Method of inhibiting complement activation The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin ... | 04/19/2011 |
| 7914789 | HEMCM42 antibodies The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted prote... | 03/29/2011 |
| 7910104 | Modified anti-CD52 antibody The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity. ... | 03/22/2011 |
| 7897149 | Fully human anti-VAP-1 monoclonal antibodies Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-... | 03/01/2011 |
| 7883703 | Methods of modulating immunity The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 an... | 02/08/2011 |
| 7862818 | Method of inhibiting human G-protein chemokine receptor (CCR5) HDGNR10 The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5... | 01/04/2011 |
| 7829092 | Recombinant anti-VLA4 antibody molecules The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel ... | 11/09/2010 |
| 7820166 | Potent T cell modulating molecules The present invention relates to a polypeptide construct comprising at least one CDR3 region, wherein at least one of the at least CDR3 regions comprises at least one substitution in the amino acid sequence YYDDHY (SEQ ID NO.1) and wherein the at least one substitut... | 10/26/2010 |
| 7803376 | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeut... | 09/28/2010 |
| 7790166 | Anti-CD40 antibodies capable of blocking B-cell activation Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the... | 09/07/2010 |
| 7744884 | Neutralizing antibodies and methods of use thereof This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using t... | 06/29/2010 |
| 7682614 | Methods for inhibition of NKT cells Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus eryth... | 03/23/2010 |
| 7655230 | Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of remova... | 02/02/2010 |
| 7622116 | Method of treating inflammation using soluble IL-17RCX4 The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disea... | 11/24/2009 |
| 7618632 | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is dir... | 11/17/2009 |
| 7521052 | Methods for treating interleukin-6 related diseases A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R). ... | 04/21/2009 |
| 7521051 | Methods of upmodulating adaptive immune response using anti-PD-1 antibodies This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions ... | 04/21/2009 |
| 7498031 | Therapeutic agents for inner ear disorders containing an IL-6 antagonist as an active ingredient A therapeutic and/or preventive agent for inner ear disorders comprising an IL-6 antagonist, preferably an anti-IL-6R antibody, as an active ingredient. ... | 03/03/2009 |
| 7482003 | Treatment for asthma with α4-specific antibodies The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel ... | 01/27/2009 |
| 7462353 | Method for the treatment of inflammatory disorders A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1. ... | 12/09/2008 |
| 7438910 | Therapeutic human anti-IL1-R1 monoclonal antibody Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a ... | 10/21/2008 |
| 7438907 | Human monoclonal antibodies against CD25 Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgeni... | 10/21/2008 |
| 7435803 | Anti-CD20 antibodies and fusion proteins thereof and methods of use The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignan... | 10/14/2008 |
| 7427401 | Method of modulating leukemic cell and eosinphil activity with monoclonal antibodies A method of isolating a monoclonal antibody capable of inhibiting any one of IL-3, GM-CSF and IL-5 binding to the common receptor βc, or a monoclonal antibody capable of inhibiting the cytokines binding to a receptor analogous to βc. The meth... | 09/23/2008 |
| 7425623 | Antibody with specificity for colon cancer A binding structure which binds in, and/or to the surface of, tumour cells; a target structure displayed and/or expressed in, or on the surface of, tumour cells; a binding structure that recognises and blocks said target structure; a substance that binds to or block... | 09/16/2008 |
| 7422744 | Methods of treating cancer with alphavbeta3-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypepti... | 09/09/2008 |
| 7422745 | Methods of treating cancer with αβ-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide ... | 09/09/2008 |
